Back to Search Start Over

Alternative mechanisms for tiotropium

Authors :
Peter J. Barnes
Tobias Welte
Peter V. Dicpinigaitis
Klaus F. Rabe
Nicholas J. Gross
Kurt Racké
Jay A. Nadel
Bruce K. Rubin
Reinoud Gosens
Stephen I. Rennard
Michael Pfeifer
Eric D. Bateman
Ignaz Wessler
Molecular Pharmacology
Groningen Research Institute for Asthma and COPD (GRIAC)
Source :
Pulmonary Pharmacology & Therapeutics, 22(6), 533-542. ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD
Publication Year :
2009

Abstract

Tiotropium is commonly used in the treatment of chronic obstructive pulmonary disease. Although largely considered to be a long-acting bronchodilator, its demonstrated efficacy in reducing the frequency of exacerbations and preliminary evidence from early studies indicating that it might slow the rate of decline in lung function suggested mechanisms of action in addition to simple bronchodilation. This hypothesis was examined in the recently published UPLIFT study and, although spirometric and other clinical benefits of tiotropium treatment extended to four years, the rate of decline in lung function did not appear to be reduced by the addition of tiotropium in this study. This article summarizes data from a variety of investigations that provide insights into possible mechanisms to account for the effects of tiotropium. The report summarizes the discussion on basic and clinical research in this field. (c) 2009 Elsevier Ltd. All rights reserved.

Details

Language :
English
ISSN :
10945539
Volume :
22
Issue :
6
Database :
OpenAIRE
Journal :
Pulmonary Pharmacology & Therapeutics
Accession number :
edsair.doi.dedup.....af3f7f26bcbaa3c333d6f9229f0560bb
Full Text :
https://doi.org/10.1016/j.pupt.2009.06.002